Tocilizumab

Nature Reviews Drug Discovery

Volumn 8, Issue 4, 2009, Pages 273-274

  Scheinecker, Clemens ^a   Smolen, Josef ^a   Yasothan, Uma ^b   Stoll, Jeffrey ^b   Kirkpatrick, Peter ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PLACEBO;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; JUVENILE RHEUMATOID ARTHRITIS; LIPID BLOOD LEVEL; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, INTERLEUKIN-6;

EID: 64049108915     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2863     Document Type: Article

References (17)

1. Smolen, J. S. et al. New therapies for the treatment of rheumatoid arthritis. Lancet 370, 1861-1874 (2007).
2. Nishimoto, N. & Kishimoto, T. Interleukin 6: From bench to bedside. Nature Clin. Pract. Rheumatol. 2, 619-626 (2006).
3. Sack, U. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13, 45-51 (1993).
4. Madhok, R. et al. Serum interleukin 6 levels in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52, 232-234 (1993).
5. Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461-468 (1998).
6. Takagi N. et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41, 2117-2121 (1998).
7. Sato, K. et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
8. European Medicines Agency (EMEA). European Public Assessment Report - RoActemra. EMEA website [online], http://www.emea.europa.eu/humandocs/ PDFs/EPAR/RoActemra/H-955-PI-en.pdf (2008).
9. Jones, G. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: The AMBITION study. Ann. Rheum. Dis. 67 (Suppl. II), 89 (2008).
10. Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE Study. Arthritis Rheum. 58, 4031 (2008).
11. Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371 987-997 (2008).
12. Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968-2980 (2008).
13. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
14. Mierau, M. et al. Assessing remission in clinical practice. Rheumatology 46, 975-979 (2007).
15. Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: The impacts of remission and TNF-blockade. Ann. Rheum. Dis. 7 Jul 2008 (doi:10.1136/ ard.2008.090019).
16. IMS MIDAS (2009).
17. Therapeutic categories outlook: Arthritis & inflammation (Cowen and Company, 2008).